Table 5.
Main adverse effects during the study period among the three groups.
|
MX
(n = 38) |
MX + SPT (n = 37) |
MX + MN (n = 40) |
|
|---|---|---|---|
| Total | 27 | 45 | 24 |
| Facial hypertrichosis | 4 | 5 | 5 |
| Trichomadesis aggravating | 4 | 4 | 3 |
| Scalp pruritus | 8 | 8 | 9 |
| Increased scurf | 7 | 6 | 5 |
| Infection | 0 | 0 | 1 |
| Edema of the limbs | 0 | 1 | 0 |
| Headache | 1 | 1 | 0 |
| Palpitation | 1 | 3 | 0 |
| Postural hypotension | 1 | 0 | 1 |
| Hyperkalemia | 0 | 1 | 0 |
| Menstrual disorder | 0 | 15 | 0 |
| Urticaria | 1 | 1 | 0 |
MX, minoxidil; SPT, spironolactone; MN, microneedling.